A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pegvaliase-Pqpz (Palynziq)

Phenylalanine Metabolizing Enzyme class · 0 generic manufacturers · 0 ANDAs filed at FDA.

First FDA approval2018-05-24
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$38.2M in CY2024 Part D spend1K claims · 217 beneficiaries · 329 plans surveyed

Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
63 / 329
Limited PA friction.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Pegvaliase-Pqpz used for?

Pegvaliase-Pqpz is a Phenylalanine Metabolizing Enzyme medication tracked in Medicare Part D.

Is there a generic for Pegvaliase-Pqpz?

No. Pegvaliase-Pqpz is brand-only with no generic equivalents currently in market.

How much does my plan pay for Pegvaliase-Pqpz?

NADAC pricing data not currently available for this drug.

Is Pegvaliase-Pqpz on the FDA shortage list?

No. Pegvaliase-Pqpz is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.